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Background: Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder. Post-infectious
IBS (PI-IBS) is a subset of IBS that accounts for a large proportion of IBS patients. The PI-IBS symptoms meet the Rome
criteria for IBS with diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M). A low-grade inflammation has been
reported to occur in PI-IBS. Abnormalities in intestinal endocrine cells have been reported in both sporadic IBS and
PI-IBS.
Case presentation: A 20-year-old female with a diagnosis of IBS with constipation (IBS-C), according to Rome III
criteria, contracted Campylobacter-induced gastroenteritis, after which her symptom pattern changed to IBS-M. She
showed an intestinal low-grade inflammation that was manifested by an increase in the number of intraepithelial and
lamina propria leucocytes and lymphocytes and an increase in the density of mast cells in lamina propria. There was
also an increase in the density of intestinal serotonin and peptide YY (PYY) cells and a decrease in the density of rectal
somatostatin cells. Follow-up of the patient at 4-months post-infection revealed reduction of IBS symptoms and an
improvement in her quality of life. However, 6 months following the Campylobacter infection, the patient switched
back from IBS-M to IBS-C, probably due to recovery from PI-IBS. The patient was treated with prucalopride, which is
serotonin 5HT4 receptor agonist. Six months later following this treatment, the symptoms were reduced and the
quality of life improved in the reported patient.
Conclusions: Gastroenteritis in patients with IBS-C causes a post-infectious, low-grade inflammation. Interaction
between immune-cells and intestinal endocrine cells increases the density of certain endocrine cells, which in turn
might be responsible for the change in the symptom pattern, the milder symptoms and the improvement in the
quality of life seen in the reported patient. The findings in this case raise the question as to whether intestinal
infections are responsible for the previously reported switching of IBS from one subtype to another over time.
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Irritable bowel syndrome (IBS) is a common chronic
functional gastrointestinal disorder, that is character-
ized by frequent abdominal pain/discomfort, abdom-
inal bloating/distension and an altered stool pattern
[1-4]. Post-infectious IBS (PI-IBS) is a subset of IBS,
and is characterized as a sudden onset of IBS symp-
toms following gastroenteritis in individuals who have
had no gastrointestinal complaints [5]. The proportion
of patients developing IBS following gastroenteritis
varied between studies, from 3.7% to 36% [5]. Patients
with IBS are more common in patients presenting
with bacterial gastroenteritis to primary care physician
than community controls [6]. This may indicate that
IBS patients are predisposed to bacterial gastroenter-
itis, or that they tend to seek their doctor for bowel
symptoms more often than the background population.
Human infections caused by Campylobacter jejuni are
a leading cause of food-borne enteritis, the bacteria
usually being transmitted by the ingestion of undercooked
poultry, or contact with farm animals. This infection
leads to PI-IBS in 9-13% of cases [5,7-9]. The symp-
toms of PI-IBS meet the Rome criteria for IBS with diar-
rhoea (IBS-D) or IBS with mixed bowel habits (IBS-M)
[10-12].
In IBS, there appears to be a general depletion of
gastrointestinal endocrine cells, and especially serotonin
and PYY cells [13,14], whereas in PI-IBS there is an in-
crease in the density of these cells, especially sero-
tonin and PYY cells [1,5,11]. Furthermore, a low-grade
inflammation has been reported in PI-IBS, which is
manifested by increased intraepithelial lymphocytes and
an infiltration of mast cells in the lamina propria of
the large intestine [5,15-17]. It has been suggested that
the alterations in the population of gastrointestinal
endocrine cells and the low-grade inflammation play
a role in the pathogeneses of both sporadic and PI-
IBS [1,5,13].Table 1 Symptoms and quality of life in the patient before, d
Questionnaire Before infection During infection
Birmingham
Total score 30 35
Pain 6 15
Diarrhoea 4 20
Constipation 20 0
SF-NDI 29 48
IBS-QOLa 61 50
Six months after infection, the patient was treated with 2 mg prucalopride daily.
Birmingham, Birmingham Irritable Bowel Syndrome Symptom Questionnaire; SF-ND
Quality Of Life Questionnaire.
aPercentage of the total score.Case presentation
A 20-year-old female was investigated for recurrent
abdominal pain, abdominal distension, constipation and
nausea. She had a bowel movement every 7–10 days,
with straining at defecation and hard or lumpy stools.
She was non-smoker and was not currently taking any
medications. This patient had suffered from these symp-
toms since her childhood. Her mother had similar symp-
toms and had a diagnosis of IBS. Her symptoms affected
her schoolwork and isolated her socially; she has been
hospitalized on many occasions. The patient submitted
to a complete physical examination and was investigated
by means of blood (full blood count, electrolytes, calcium,
and inflammatory markers), liver, and thyroid function
tests. She also underwent gastroscopy with duodenal bi-
opsy sampling and colonoscopy with segmental biopsy
sampling. The findings of all these examinations and tests
were normal. The patient fulfilled Rome III criteria and
was thus given the diagnosis of IBS with constipation
(IBS-C). She was asked to complete the three following
questionnaires (Table 1): Birmingham IBS Symptom
scores, Short-Form Nepean Dyspepsia Index (SF-NDI)
measuring the reduction in quality of life and Irritable
Bowel Syndrome quality of life (IBS-QOL) [18-20]. She
was then submitted to a non-pharmacological treatment
program at our clinic, which includes provision of infor-
mation and reassurance, dietary guidance, regular exercise
and regular intake of probiotics [21]. Her symptoms sub-
sequently reduced and her quality of life improved.
Seven months later, the patient was referred to the
causal department because of a 3-day history of bloody
diarrhoea occurring between 10 to 15 times daily, ex-
treme fatigue and dehydration. She did not have a fever
and with the exception of C-reactive protein (CRP),
which was 17 mg/l (normal range 0–10 mg/l), her blood
tests were normal. Colonoscopy revealed severe colonic
inflammation with erythema, oedema, friable mucosae,
haemorrhagic spots and ulcers. Biopsy samples takenuring and after Campylobacter infection
After infection
2 months 4 months 6 months 12 months
26 18 29 4
4 3 6 2
12 8 5 0
10 7 20 2
20 17 28 13
84 86 60 94
I, Short-Form Nepean Dyspepsia Index; IBS-QOL, Irritable Bowel Syndrome
Figure 1 Leucocytes in the patient before Campylobacter infection (A), during (B) and 4-months after (C) Campylobacter infection.
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ture. However, a focal increase in the density of immune
cells in the lamina propria and focal cryptitis and crypt
abscesses were observed. Stool culture was positive for
Campylobacter jujeni. The patient was treated with
400-mg metronidazole, twice daily for 2 weeks.
The findings of a physical examination and blood tests
performed at follow-up visits at the outpatient clinic 2,
4, 6 and 12 months after Campylobacter infection were
normal. Colonoscopy at 2 and 4 months visits revealed a
normal endoscopic appearance. Moreover, the patient’s
general condition was improved. Her symptom pattern
had changed and she experienced an improvement in her
quality of life (Table 1). Reassessment of her symptoms
according to Rome III criteria put the patient into the
IBS-M subtype. Six months following the Campylobacter
infection, the patient suffered from abdominal pain,
abdominal distension, constipation and nausea in the
same degree as before the infection. She was treated
with 2 mg prucalopride daily. Six months later, the
patient’s symptom was reduced and her quality of life
improved (Table 1).
Colonic and rectal biopsy samples obtained during
colonoscopy before, during, and 2 and 4 months after
Campylobacter infection were fixed overnight in 4% buff-
ered paraformaldehyde, embedded in paraffin, and cut intoFigure 2 Mast cells in the lamina propria before Campylobacter infect5-μm sections. The sections were immunostained with
the avidin-biotin –complex (ABC) method using Vectastain
ABC-kit and 3,3′-diaminobenzidine (DAB) peroxidase
Substrate Kit (Vector laboratories). The sections were in-
cubated with the primary antiserum/antibody at room
temperature for 2 h. The sections were then washed
in PBS buffer and incubated with biotinylated swine
anti-mouse (in the case of monoclonal antibodies) or
anti-rabbit IgG (in the case of polyclonal antibodies) di-
luted 1:200 for 30 min at room temperature. After wash-
ing the slides in PBS buffer, the sections were incubated
for 30 min with avidin-biotin-peroxidase complex diluted
1:100, and then immersed in 3,3′-diaminobenzidine (DAB)
peroxidase substrate, followed by counterstaining in
hematoxylin. The following primary antisera/antibodies
were used: monoclonal mouse anti-N-terminal of purified
Chromogranin A (Dako, code no. M869), monoclonal
mouse anti-serotonin (Dako, code no. 5HT-209), polyclonal
anti-porcine peptide PYY (Alpha-Dagnostica, code PYY
11A), polyclonal rabbit anti-synthetic-human PP (Diagnostic
Biosystems, code no. #114), polyclonal rabbit anti-porcine
glicentin/glucagon (Acris Antibodies, code BP508), poly-
clonal rabbit anti-synthetic-human somatostatin (Dako, code
no. A566); monoclonal mouse anti-human CD45 (Dako,
code no. M0701), monoclonal mouse anti-human CD47
(Dako, code no. I5647), monoclonal mouse anti-humanion (A) and (B) 4- months after Campylobacter infection.
Table 2 Number of colonic intraepithelial (IE) and lamina
propria (LP) immune cells before, during and after
Campylobacter infection
Cell type Before
infection
During
infection
After infection Controlsc 95%
confidence
interval
2
months
4
months
Leucocytes
in LPa
69 268 102 199 81-118
Leucocytes
in IEb
110 224 162 150 78-115
Lymphocytes
in LPa
3 39 2 2 0-5
Lymphocytes
in IEb
1 6 7 8 0-2
Mast cellsa 7 17 11 12 6-10
Quantifications of cells were conducted in ten randomly chosen fields using
the Olympus CellSense software.
aNumber of cells per field.
bNumber of cells per mm2 of epithelium.
cThe control group comprised 27subjects (16 females and 11 males; mean age
52 years, range 20–69 years) who had submitted to colonoscopy for the
following reasons: gastrointestinal bleeding, where the source of bleeding was
identified as haemorrhoids (n=18), or angiodysplasia (n=2), and health worries
resulting from a relative being diagnosed with colon carcinoma (n=7).
Table 4 Endocrine cell densities in the colon before,
during and after Campylobacter infection
Cell type Before
infection
During
infection
After infection Controls
95%
confidence
interval
2
months
4
months
Chromogranin A 7 59 50 20 32-43
Serotonin 5 32 32 28 27-32
PYY 4 29 20 15 6-10
Quantifications and controls are the same as in Table 2.
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anti-human mast cell tryptase (Dako, code no. M7052).
CD45 is considered as a leucocyte common antigen and is
expressed exclusively on cells of the hematopoietic system
and their progenitors. CD57 is expressed by subsets of NK
cells and CD8+ lymphocytes, and by a small percentage of
CD4+/CD45R0+ T lymphocytes. CD68 labels human
monocytes, macrophages and myeloid cells. Human mast
cell tryptase comprise a family of trypsin-like neutral
serine proteases that are predominantly expressed in mast
cells. The total leucocytes, lymphocytes and mast cells, as
well as chromogranin A, serotonin, peptide YY (PYY), and
somatostatin cells. The densities of these cells were quan-
tified by computerized image analysis using Olympus
cellSens imaging software (version 1.7) on a computer
linked to an Olympus microscope type BX 43 with anTable 3 Densities of rectal IE and LP immune endocrine
cells before, during and after Campylobacter infection
Cell type Before
infection
During
infection
After infection Controls 95%
confidence
interval
2
months
4
months
Leucocytes
in LP
71 298 104 202 82–112
Leucocytes
in IE
105 224 172 153 81–120
Lymphocytes
in LP
1 42 2 2 0-6
Lymphocytes
in IE
2 7 7 9 0-2
Mast cells 9 19 14 15 9-12
Quantifications and controls are the same as in Table 2.Olympus camera (DP 26). A ×40 objective was used,
for which each frame (field) on the monitor represented a
tissue area of 0.14 mm2 of the tissue. The number
intraepithelial leucocytes cells and the endocrine cells as
well as the area of the epithelial cells were measured in
each field. The number of leucocytes, lymphocytes, and
mast cells in lamina propria were counted per microscopic
field. All measurements were done in 10 randomly chosen
fields for each individual.
The densities of both intraepithelial and lamina
propria leucocytes and lymphocytes were increased in
both the colon and rectum at 2 and 4 months after the
Campylobacter infection (Figure 1), as were the number
of mast cells in the lamina propria in both the colon
and rectum (Figure 2, Tables 2 and 3). The total
number of endocrine cells in the colon and rectum prior
to Campylobacter infection (as detected by chromogranin
A staining) was low, but within the normal limits (Tables 4
and 5). This is in agreement with previously published
results in IBS-C patients [22,23]. Although chromogranin
A is used as a common marker for peptide hormone
containing cells, chromogranin A immunoreactivity varies
between gastrointestinal segments and even within popu-
lation of the same endocrine cell type [24]. It has been
found that chromogranin A- immunoreactive cells are not
representative of the entire population of endocrine cells
and that they are the least numerous of all of the endo-
crine cells combined [25]. The densities of serotonin and
PYY cells had increased in both the colon and rectum dur-
ing, 2 and 4 months post-infection (Figure 3). However,Table 5 Densities of rectal endocrine cells before, during
and after Campylobacter infection
Cell type Before
infection
During
infection
After infection Controls
95%
confidence
interval
2
months
4
months
Chromogranin A 35 154 50 65 108–136
Serotonin 21 83 32 43 32–51
PYY 16 49 24 29 54–67
Somatostatin 22 9 3 15 14–20
Quantifications and controls are the same as in Table 2.
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rectum during and after Campylobacter infection.
Discussion
Consistent with previously published observations, the
present case developed a low-grad inflammation following
Campylobacter infection [1,5,11,16,26-31]. An increase in
the densities of intestinal endocrine cells, and especially
serotonin and PYY cells, has been reported in Crohn’s
disease, ulcerative colitis and lymphocytic colitis [32-35].
An increase in the density of intestinal endocrine has
also been described in PI-IBS [5,11,15,16,28,30,31,33].
Several studies have shown that inflammation and im-
mune cells affect the neuroendocrine system of the
gut (the endocrine/immune axis) [1,36]. It seems that
infection/inflammation induces an increase in the popu-
lation of certain gut endocrine cells through an interaction
between those cells and immune cells [1,36].
The pattern of symptoms in the present patient changed
from IBS-C to IBS-M with much less abdominal pain.
Serotonin activates the submucosal sensory branch of the
enteric nervous system, and controls gastrointestinal mo-
tility and chloride secretion via inter-neurons and motor
neurons [13,37-42]. PYY delays gastric emptying, inhibits
gastric and pancreatic secretion, and is a major ileal brake
mediator [13,43,44]. Moreover, PYY inhibits prostaglandin
(PG) E2 and vasoactive intestinal peptide (VIP), both of
which stimulate intestinal secretion [13,45-47]. Ad-
ministration of PYY inhibits diarrhoea in experimental
animals by reducing intestinal fluid secretion and
slowing colon transit [13,48]. Somatostatin inhibits in-
testinal contraction, and inhibits gut exocrine and
neuroendocrine secretion [13]. It is therefore conceiv-
able, that the changes in the present patient’s symptoms
are attributable to the reported changes in the density of
the endocrine cells.
It is not uncommon for IBS patients to switch from
one subtype to another over time [49-52]. The patient
presented here switched from the IBS-C subtype to the
IBS-M subtype following a bout of gastroenteritis, and it
is possible that intestinal infection was the underlyingFigure 3 Serotonin immunoreactive cells before (A), during (B) and 4cause of this switch. However, 6 months following the
Campylobacter infection, the patient switched back from
IBS-M to IBS-C. Campylobacter jejuni produces a range
of toxins including cytolethal distending toxin (24),
which first produces secretory diarrhoea in the small in-
testine early in the illness, after which there is invasion
of the distal ileum and colon to produce an inflamma-
tory ileocolitis, which can extend all the way to the rec-
tum [53]. It has been reported that PI-IBS symptoms
following Campylobacter infection decline with time
[54-56]. It is conceivable, therefore, to conclude that the
patient returning to her original symptoms represent a
recovering form PI-IBS.
The symptoms were reduced and the quality of life im-
proved in the patient following the treatment with
prucalopride, which is a highly selective serotonin 5HT4
receptor agonist that has been shown to stimulate gut
motility [57]. The patient disclosed a low density of co-
lonic serotonin cells, which is in line with previously
published observations in IBS patients [14]. This may
explain why a serotonin agonist was effective in the
treatment of the reported patient.
Conclusions
Gastroenteritis due to Campylobacter infection in pa-
tients with IBS-C causes low-grade inflammation and
changes in the densities of intestinal endocrine cells.
These changes may be responsible for the change in
symptom pattern and the switch from IBS-C to IBS-M
that were observed in the reported patient. The pa-
tient switched back to IBS-C, 6 months following the
Campylobacter infection, probably as a recovery from
IP-IBS. Furthermore, treatment with serotonin agonist
was successful in the reported patient, who disclosed re-
duced colonic serotonin cell density.
Consent
Written informed consent was obtained from the patient
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